rss
Eur J Hosp Pharm 20:A219 doi:10.1136/ejhpharm-2013-000276.607
  • Clinical pharmacy and clinical trials (including case series)

CPC-150 Tuberculosis and Systemic Diseases

  1. M Guerfali
  1. Hospital the “Rabta”, Pharmacy, Tunis, Tunisia

Abstract

Background The immunosuppression of systemic diseases makes the management of patients with tuberculosis more complicated.

Purpose To monitor the clinical evolution of tuberculosis in patients suffering from systemic diseases.

Materials and Methods A retrospective study, from 1998 to 2012, in the internal medicine service in Rabta hospital, Tunisia, of 9 patients (8 women and a man, median age: 54 years) suffering from connective tissues disease, treated by corticosteroids linked in one or several treatments to immunosuppressants, who subsequently developed tuberculosis.

Results The median time to diagnosis was 116 days (7d – 1 year). The location of the tuberculosis was pulmonary (n = 2), ganglionic (n = 3), urogenital (n = 2), tubercular spondylodiscitis (n = 1), more than one location (n = 1). The diagnosis of tuberculosis was confirmed by bacteriology (n = 4) four cases, histologically (n = 5) and by a test treatment (n = 1). Systemic illnesses were: systemic lupus erythematous (n = 5), Gougerot-Sjögren syndrome (secondary or primary) (n = 3), sarcoidosis (n = 1), systemic scleroderma linked to pernicious anaemia (n = 1), rheumatoid arthritis (patient 2 linked to lupus) (n = 1) and multiple auto-immune syndrome (n = 1). The diagnosis of systematic illness was made before that of tuberculosis in 8 patients and concomitantly in only one. Under treatment by four drugs then by two drugs, the evolution of tuberculosis was favourable in five of nine patients. One of the patients developed an allergy in isoniazid and resistance to the anti-tubercular treatment. Five of our patients recovered from their illness.

Conclusions This study confirms the often extra-pulmonary character of tuberculosis in patients with systemic disease as well as the difficulty of diagnosis and problems multiplied by this association.

No conflict of interest.

EJHP blog

Analysis and discussion of the latest news, research findings and policy developments in hospital pharmacy.

Visit the blog >>

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EJHP.

View free sample issue >>

Email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article